地塞米松EP杂质E T17217

Product Introduction
Bioactivity


英文名: Vamorolone

描述: Vamorolone (VBP15) 是一种首创的，具有口服活性的解离性类固醇 (dissociative steroidal) 抗炎药和膜稳定剂。它抑制 (NF-κB) 抑制作用，并降低了激素的影响。它改善肌营养不良，无副作用。

体外活性: Vamorolone is a first-in-class mineralocorticoid receptor antagonist/dissociative glucocorticoid receptor ligand. Vamorolone inhibits TNFα-induced pro-inflammatory NF-κB signaling in C2C12 muscle cells at 1 nM or more. Vamorolone binds the glucocorticoid receptor and mineralocorticoid receptor. Vamorolone (0.1, 1μM; 30 minutes) decreases the production of IL1βand CCL5 inflammatory mediators in primary human macrophages [1][2][3].

体内活性: Vamorolone (30 mg/kg; p.o.; daily for 20 days) decreases CNS Inflammation in murine experimental autoimmune encephalomyelitis. Vamorolone (5-30 mg/kg; cherry syrup) displays a superior side effect profile compared to pharmacological glucocorticoids in mdx mice [1][2].

存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度: DMSO : 62.5 mg/mL (175.34 mM)


关键字: inhibit | repair | Mineralocorticoid Receptor | Glucocorticoid Receptor | NF-κB | VBP 15 | inflammation | Duchenne | Vamorolone | Inhibitor | membrane | dystrophy | Nuclear factor-κB | VBP-15 | Nuclear factor-kappaB | muscular | glucocorticoid

相关产品: GSK9027 | GW-870086 | Finerenone | Prednisolone disodium phosphate | 6α-Methylprednisolone 21-hemisuccinate sodium salt | Halcinonide | Corticosterone | Fluorometholone | Medrysone | Ecdysone

相关库: Antioxidant Compound Library | FDA-Approved Drug Library | Drug Repurposing Compound Library | Anti-Cancer Compound Library | Anti-Cancer Drug Library | Human Metabolite Library | Inhibitor Library | Anti-Cancer Clinical Compound Library | Pediatric Drug Library | Preclinical Compound Library

地塞米松EP杂质E T17217信息由TargetMol中国为您提供，如您想了解更多关于地塞米松EP杂质E T17217报价、型号、参数等信息，欢迎来电或留言咨询。

注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途